Volume 95 Issue 11 | pp. 28-29
Issue Date: March 13, 2017

Pharmaceutical firms see modest growth in 2016

Individual company results were mixed as major products were beset by patent squabbles and expirations
Department: Business
Keywords: finance, pharmaceuticals, biopharmaceuticals, sales, earnings

It was a rocky year for the pharmaceutical industry in 2016, made even more uneasy by infighting among companies.

Dynamics stemming from the U.S. presidential election, mergers, pricing, and global markets pushed and pulled drug company fortunes in many directions. Leading drugs experienced competitive and legal threats in what seemed a particularly litigious year filled with disputes among most major firms.

Even so, the 18 companies that C&EN tracks fared . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society